journal
MENU ▼
Read by QxMD icon Read
search

American Health & Drug Benefits

journal
https://www.readbyqxmd.com/read/29263775/the-value-of-pre-fda-approval-healthcare-economic-information-exchange-between-payers-and-drug-manufacturers
#1
Peter R Fendt, Brian Ung, F Randy Vogenberg
No abstract text is available yet for this article.
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263774/comparing-the-cost-of-treatment-with-octreotide-long-acting-release-versus-lanreotide-in-patients-with-metastatic-gastrointestinal-neuroendocrine-tumors
#2
Rajeev Ayyagari, Maureen Neary, Shang Li, Ariel Rokito, Hongbo Yang, Jipan Xie, Al B Benson
Background: The 2 somatostatin analogs currently recommended by the National Comprehensive Cancer Network for the treatment of gastrointestinal (GI) neuroendocrine tumors (NETs) include octreotide long-acting release (Sandostatin LAR) for injectable suspension and lanreotide (Somatuline Depot) injection for subcutaneous use. Objective: To estimate the costs to payers associated with 30-mg octreotide LAR and 120-mg lanreotide treatment among patients with metastatic GI-NETs...
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263773/major-cardiovascular-events-in-patients-with-gout-and-associated-cardiovascular-disease-or-heart-failure-and-chronic-kidney-disease-initiating-a-xanthine-oxidase-inhibitor
#3
JoAnne Foody, Robin S Turpin, Beni A Tidwell, Debra Lawrence, Kathy L Schulman
Background: Several observational studies and meta-analyses have suggested that treating hyperuricemia in patients with gout and moderate or severe chronic kidney disease (CKD) may improve renal and cardiovascular (CV) outcomes. Objective: To evaluate the impact of initiating allopurinol or febuxostat treatment on major CV events in patients with gout, preexisting CV disease (CVD) or heart failure (HF), and stage 3 or 4 CKD in a real-world setting. Methods: Patients with gout (aged >18 years) who initiated allopurinol or febuxostat treatment between 2009 and 2013 after a diagnosis of stage 3 or 4 CKD and CVD-including coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (PVD)-or HF were selected from the MarketScan databases...
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263772/-opioids-equal-heroin
#4
EDITORIAL
David B Nash
No abstract text is available yet for this article.
November 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263771/the-cost-of-hematopoietic-stem-cell-transplantation-in-the-united-states
#5
Michael S Broder, Tiffany P Quock, Eunice Chang, Sheila R Reddy, Rajni Agarwal-Hashmi, Sally Arai, Kathleen F Villa
Background: Hematopoietic stem-cell transplantation (HSCT) requires highly specialized, resource-intensive care. Myeloablative conditioning regimens used before HSCT generally require inpatient stays and are more intensive than other preparative regimens, and may therefore be more costly. Objective: To estimate the costs associated with inpatient HSCT according to the type of the conditioning regimen used and other potential contributors to the overall cost of the procedure...
October 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263770/economic-impact-of-increased-utilization-of-multivariate-assay-testing-to-guide-the-treatment-of-ovarian-cancer-implications-for-payers
#6
Burton S Brodsky, Gary M Owens, Dennis J Scotti, Keith A Needham, Christina L Cool
Background: Ovarian cancer is the eighth most common cancer among women, but ranks fifth in cancer-related causes of death, the majority of which are detected in late stages, after the cancer has metastasized. The CA125 test is the standard of care for assessing suspicious pelvic masses. However, the primary use of CA125 is to monitor treatment progress rather than to screen for disease, and its sensitivity is exceedingly low, unlike the multivariate assay OVA1. A cost-effective treatment of ovarian cancer requires early and accurate diagnosis of pelvic masses and reduced referrals of patients with benign tumors to a gynecologic oncologist...
October 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29263769/trending-bio
#7
EDITORIAL
David B Nash
No abstract text is available yet for this article.
October 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975014/the-relative-burden-of-menopausal-and-postmenopausal-symptoms-versus-other-major-conditions-a-retrospective-analysis-of-the-medical-expenditure-panel-survey-data
#8
Annlouise R Assaf, Andrew G Bushmakin, Nina Joyce, Michael J Louie, Michael Flores, Margaret Moffatt
BACKGROUND: The direct costs associated with menopausal and postmenopausal symptoms (hereafter "menopausal symptoms") may include the costs of physician and emergency department visits, medications, laboratory testing, and the management of side effects. However, much remains unknown about the costs related to menopausal symptoms, including how they compare with the costs of other diseases that are common among menopausal women. OBJECTIVE: To compare the economic burden of menopausal symptoms with other select prevalent chronic conditions among a nationally representative sample of US menopausal women aged 45 to 65 years...
September 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975013/medication-adherence-treatment-patterns-and-dose-reduction-in-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-abiraterone-acetate-or-enzalutamide
#9
Ajay S Behl, Lorie A Ellis, Dominic Pilon, Yongling Xiao, Patrick Lefebvre
BACKGROUND: The efficacy of and overall survival associated with metastatic castration-resistant prostate cancer (CRPC) treatments rely on patients' consistent adherence to the recommended dosage regimens. OBJECTIVES: To evaluate treatment patterns and patient adherence to abiraterone acetate or enzalutamide therapy in real-world practice, and to examine the factors that may be associated with medication dose reduction in patients with metastatic CRPC. METHODS: Retrospective analyses were conducted using the Truven Health MarketScan research databases among patients with metastatic CRPC who initiated treatment with abiraterone acetate or enzalutamide between October 1, 2012, and December 31, 2014 (index date)...
September 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975012/costs-and-effectiveness-of-mindfulness-based-art-therapy-versus-standard-breast-cancer-support-group-for-women-with-cancer
#10
Katherine M Prioli, Laura T Pizzi, Kathryn M Kash, Andrew B Newberg, Anna Marie Morlino, Michael J Matthews, Daniel A Monti
BACKGROUND: The results of several studies have demonstrated that women and men with a cancer diagnosis benefit from interventions to reduce distress and improve quality of life (QOL). However, little is known about the costs and effectiveness of such interventions. Identifying a stress-reduction program that is low cost and effective is important for payers, employers, and healthcare professionals, as well as for patients with cancer. OBJECTIVE: To evaluate the direct costs and effectiveness of the mindfulness-based art therapy (MBAT) program compared with the cost and effectiveness of a breast cancer support group (BCSG)...
September 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975011/health-inequities-in-america
#11
EDITORIAL
David B Nash
No abstract text is available yet for this article.
September 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975010/budget-impact-of-a-comprehensive-nutrition-focused-quality-improvement-program-for-malnourished-hospitalized-patients
#12
Suela Sulo, Josh Feldstein, Jamie Partridge, Bjoern Schwander, Krishnan Sriram, Wm Thomas Summerfelt
BACKGROUND: Nutrition interventions can alleviate the burden of malnutrition by improving patient outcomes; however, evidence on the economic impact of medical nutrition intervention remains limited. A previously published nutrition-focused quality improvement program targeting malnourished hospitalized patients showed that screening patients with a validated screening tool at admission, rapidly administering oral nutritional supplements, and educating patients on supplement adherence result in significant reductions in 30-day unplanned readmissions and hospital length of stay...
July 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975009/value-frameworks-in-oncology-comparative-analysis-and-implications-to-the-pharmaceutical-industry
#13
REVIEW
Mark Slomiany, Priya Madhavan, Michael Kuehn, Sasha Richardson
BACKGROUND: As the cost of oncology care continues to rise, composite value models that variably capture the diverse concerns of patients, physicians, payers, policymakers, and the pharmaceutical industry have begun to take shape. OBJECTIVES: To review the capabilities and limitations of 5 of the most notable value frameworks in oncology that have emerged in recent years and to compare their relative value and application among the intended stakeholders. METHODS: We compared the methodology of the American Society of Clinical Oncology (ASCO) Value Framework (version 2...
July 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975008/emphasize-shared-decision-making-between-physicians-and-patients-to-improve-diabetes-outcomes
#14
Gary Branning, Stacey L Worthy, Martha Vater
No abstract text is available yet for this article.
July 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975007/the-medical-and-economic-burden-of-narcolepsy-implications-for-managed-care
#15
REVIEW
Michael J Thorpy, George Hiller
BACKGROUND: The neurologic disorder narcolepsy results from dysregulation of the sleep-wake cycle and is primarily characterized by chronic, severely excessive daytime sleepiness and cataplexy, an emotionally induced muscle weakness. The prevalence of narcolepsy is approximately 0.05%, and onset generally occurs during the first 2 decades of life. Narcolepsy is believed to be an autoimmune disorder with destruction of hypocretin-producing neurons in the lateral hypothalamus. OBJECTIVES: To provide an enhanced understanding of narcolepsy and establish the need for early diagnosis and rapid initiation of effective treatment for patients with narcolepsy...
July 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28975006/commencement-2017
#16
EDITORIAL
David B Nash
No abstract text is available yet for this article.
July 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28794824/the-clinical-and-economic-burden-of-hyperkalemia-on-medicare-and-commercial-payers
#17
Kathryn Fitch, J Michael Woolley, Tyler Engel, Helen Blumen
BACKGROUND: Hyperkalemia (serum potassium >5.0 mEq/L) may be caused by reduced kidney function and drugs affecting the renin-angiotensin-aldosterone system and is often present in patients with chronic kidney disease (CKD). OBJECTIVE: To quantify the burden of hyperkalemia in US Medicare fee-for-service and commercially insured populations using real-world claims data, focusing on prevalence, comorbidities, mortality, medical utilization, and cost. METHODS: A descriptive, retrospective claims data analysis was performed on patients with hyperkalemia using the 2014 Medicare 5% sample and the 2014 Truven Health Analytics MarketScan Commercial Claims and Encounter databases...
June 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28794823/challenges-and-opportunities-in-managing-type-2-diabetes
#18
Laura Morgan
No abstract text is available yet for this article.
June 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28794822/overview-of-glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-patients-with-type-2-diabetes
#19
Kelvin Lingjet Tran, Young In Park, Shalin Pandya, Navin John Muliyil, Brandon David Jensen, Kovin Huynh, Quang T Nguyen
BACKGROUND: It is estimated that 29.1 million people or 9.3% of the US population have diabetes, which contributes to considerable medical and financial burden. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion impairment leading to hyperglycemia. The presence of insulin resistance is strongly correlated with obesity. OBJECTIVE: This article reviews the available glucagon-like peptide-1 (GLP-1) receptor agonists and their role in the management of patients with diabetes, to help guide the selection of the most suitable agent for the individualized treatment of patients with type 2 diabetes...
June 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28794821/comparing-medication-adherence-and-persistence-among-patients-with-type-2-diabetes-using-sodium-glucose-cotransporter-2-inhibitors-or-sulfonylureas
#20
Kelly F Bell, Katherine Cappell, Michael Liang, Amanda M Kong
BACKGROUND: Patients with type 2 diabetes treated with pharmacotherapy should be adherent to and persistent with their medications to experience glycemic control and prevent associated complications. OBJECTIVE: To compare medication adherence and persistence among patients with type 2 diabetes who are newly initiating a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a sulfonylurea. METHODS: This was a retrospective, observational cohort study using the MarketScan claims databases...
June 2017: American Health & Drug Benefits
journal
journal
48448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"